Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Ap...(n the area of photonics. TheInstitute's ...),Health
Navigation Links
Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications
Date:10/14/2008
n the area of photonics. The Institute's research interests include semiconductor materials and devices, practical, all solid state lasers, micro-LED arrays and a wide range of applications particularly in biophotonics. The Institute of Photonics is based in Strathclyde's Glasgow city centre campus. The IoP undertakes contract and collaborative research with industry and offers consultancy. It has a large number of PhD and EngD students, and licences technologies to companies.
For more information contact:
John Caldwell
Corporate Communications
Element Six
Tel: +353-(0)61460015
Email: info@e6.com
Institute of Photonics
University of Strathclyde
Wolfson Centre
106 Rottenrow
Glasgow G4 0NW
Tel: +44-141-548-4120
Fax: +44-141-552-1575
Email: info@photonics.ac.uk
'/>"/>
| SOURCE Element Six Ltd Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting
2. Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center
3. Novel imaging approach may assist in predicting success of treatment for atrial fibrillation
4. NIH Awards a Phase I Small Business Innovative Research Grant on "Novel Laser Scanning Technology for Computed Radiography" to VIXAR and iCRco
5. Novel tuberculosis vaccine in Germany in clinical phase
6. VCU Massey Cancer Center spearheads novel clinical study for lymphoma patients
7. Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis
8. Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008
9. NIH scientists find a novel mechanism that controls the development of autoimmunity
10. Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of the Total Pain Drug Market by 2023
11. Novel Diagnostic Marker for Acute Kidney Injury Previewed at Abbott-Sponsored Scientific Workshop
Post Your Comments:
(Date:1/8/2009)...iday, January 9 , , WASHINGTON, Jan. 8 /PRNews...rnational Union (SEIU) President Andy Stern conven...cutive Board to discuss the forced transfer of 65,...United Healthcare Workers-West (UHW), its third la...til tomorrow. , , According to reports, several...
(Date:1/8/2009)...ape new treatments for secondary pneumonia , , ...Scientists at St. Jude Children,s Research Hospita... bacterial pneumonia following influenza. They fou...in, which kill bacteria by inhibiting their protei...rst-line treatment with the "beta-lactam" antibiot...
(Date:1/8/2009)...search Hospital have demonstrated a more effective...enza. They found that the antibiotics clindamycin ...g their protein synthesis, are more effective than...ctam" antibiotic ampicillin, which causes the bact...tant because pneumonia, rather than the influenza ...
(Date:1/8/2009)...9 Continues Growth Trend , , NORTH HOLLYWOOD, C...spitalist Company, Inc. (Nasdaq: IPCM ), a leadi...ompany, announced today that it has acquired the h...nts, Inc. (MACC) in St. Louis, Missouri. The acqui...ouis market, where IPC has established a significa...
Breaking Medicine News(10 mins):Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2[0] SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed[0] Study Finds More Effective Treatment for Pneumonia Following Influenza[1] Study finds more effective treatment for pneumonia following influenza[0] IPC The Hospitalist Company Acquires Missouri Practice Group
...it brings with it the risk of tick bites and Rocky...illnesses, researchers //are looking at the role p...reen tea and vitamins C and E in preventing infect...nal Institute of Allergy and Infectious Disease, p...
... Center have developed a pioneering genomic test t...ents will need chemotherapy// and which patients c...otentially save thousands of lives by recommending...ently advised against it. The test's promising re...
...che," researchers at the Samsung Medical Center in...ain medication// , following an exercise regimen a...transformed migraines to normal migraine. Transfo... daily headache occurs when individuals begin to e...
...lebrating his 80th birthday at the Thayer Hotel at...e, he will be presented// with the 22nd Joslin Vic...lobal leader in diabetes research, care and educat... type I diabetes for 75 years. Apparently, the hot...
Other Medicine News:Health News:Antioxidants Could Halt Rocky Mountain Spotted Fever 2Health News:New Test For Early-Stage Lung Cancer 2Health News:New Test For Early-Stage Lung Cancer 3Health News:New Test For Early-Stage Lung Cancer 4Health News:Recognition for 75 Years with Type 1 Diabetes!! 2Health News:Recognition for 75 Years with Type 1 Diabetes!! 3(Date:1/8/2009)... initial dose in an ongoing Phase Ib trial demonst...three days , , Conference Call Today at 8:30AM ...l/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS...f an ongoing Phase Ib clinical trial of ANA598, th...ase inhibitor. ANA598 was very well-tolerated and...
(Date:1/7/2009)...ts in Development Based On Osteotech,s Proprietary...oRegeneration; FDA Filing Anticipated in Third Qua...ire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OST...oducts for regenerative healing, announced today t...its DuraTech(TM) BioRegeneration Matrix. The first...
(Date:1/6/2009)...PRNewswire/ -- In recent controlled studies conduc... , scientists found that the patented ingredient i...ly proven ingredient to increase levels of nitric ...itrate/nitrate (NOx) in human subjects. , , Nit...rease in blood flow to the skeletal muscles. This...
(Date:1/6/2009)...ary 6 , - Early R...n Until,December 2011 , - Expansion of the...iscovery in Ophthalmology , - Revised Comme...ublicenses to a Third Party , ExonHit The...nforcement,of its existing drug discovery collabo...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Linkwell Corp to File to Extend Filing Date for 2007 Form 10 K 15566 1Linkwell Corp to File to Extend Filing Date for 2007 Form 10 K 15566 2National Press Club to Host NEWSMAKER Media Briefing on Improving the Cost of Healthcare with R Kerry Clark 15563 1Dynatronics Introduces New Synergie Elite Aesthetic Line 15560 1Dynatronics Introduces New Synergie Elite Aesthetic Line 15560 2Medical Mutual of Ohio Earns Top Accreditation for Product Excellence 15557 1Medical Mutual of Ohio Earns Top Accreditation for Product Excellence 15557 2[0] ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients[0] Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix[0] US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream[2] ExonHit Therapeutics Expands Strategic Collaboration With Allergan
...03, 2007 /PRNewswire-FirstCall/ --,Phosphagenics L...,intends to initiate a Phase 1b clinical trial to ...d formulation of its transdermal,insulin product, ...e trial is expected to commence in the second quar...ed as a novel "needle-free",way of administering i...
... WIRE)--May 3, 2007 - Xanthus,Pharmaceuticals, Inc...M) reversed the clinical and pathological signs of...clerosis. The presentation,was made by Stephen J. ...t the University of Western Ontario, London, Ontar...ster session at the,59th American Academy of Neuro...
Other Medicine Technology:Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical,Trial in Second Quarter 2Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex 2Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex 3...Single Head Rectangular Camera ,IS2s Single ...ole body scans and SPECT studies. Offering flexibi...ingle Rectangular Head Camera is an ideal camera f...purpose work, and also acquires excellent cardiac ...
...Arctic Circler uses the same cryoconsole and platf...in the pulmonary veins. Arctic Circler is an ablat...liative-only treatments that rely on medication.,...catheter has the ability to create curvilinear les...
...Aneurysm occlusion is the ultimate objective of ne...num coils. With Matrix Detachable Coils, occlusion...ls are intended for embolization of those intracra..., their location, or the patient's general medical...
Tungsten Carbide wire twister.
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |